Introduction
More than 180 million people worldwide are infected with the chronic hepatitis C virus (HCV), a major cause of liver cirrhosis, whose life-threatening complications include liver failure, portal hypertension and hepatocellular carcinoma [1] . In patients infected with HCV genotype 1, the chances of a sustained virologic response (SVR) with the previous standard of care treatment (Peg-IFN-α + ribavirin) are only 40 -50%. Triple therapy, with DAA in combination with Peg-IFN-α + ribavirin, is the new standard of care for chronic hepatitis C treatment in genotype 1-infected patients [2] .
Two NS3-4A protease inhibitors (boceprevir and telaprevir) are highly potent and were approved in Europe and in the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1 [3] .
Treatment with available direct-acting antiviral (DAA) drugs has increased sustained virologic response (SVR) rates in genotype 1 infection and shortened duration of therapy in many patients, but these agents have a low barrier to resistance. Initial monoterapy studies of these agents showed prompt suppression of viral activity and rapid emergence of resistance, requiring that they could be administered along with a interferon alfa and ribavirin to prevent resistance, 12 weeks and 24 weeks after stopping DAA treatment [3] [4] .
Objective
The study analyses the effect of triple therapy including DAA (Telaprevir for 12 weeks) in terms of tolerability and efficiency.
Material and method A lot of 24 patients was included in the study, who have concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. The study was conducted in accordance to the declaration of Helsinki. (or between the screening and baseline visit), unless they had a contraindication for procedure or any evidence of portal hypertension not associated with cirrhosis. For patients who had a liver biopsy performed more than 2 years prior to screening or without a biopsy (in case of a contraindication or portal hypertension), a non-invasive staging assessment was required, such as FibroScan, MRElastography, or FibroTest/FibroSure, which should have not been older than 6 months prior to screening. -Chronicity of hepatitis C virus (HCV) infection, as confirmed by one or both of the following: presence of anti-HCV antibody and/or HCV ribonucleic acid (RNA) at least 6 months prior to the screening visit and/or presence of fibrosis on biopsy. -Genotype 1 HCV infection with plasma HCV RNA of >10,000 IU/mL (both confirmed at screening). The patients were evaluated at screening visit in clinical (physical examinations) and paraclinical terms: laboratory tests (HLG, biochemical analysis, urine collection, virus C genotype), liver biopsy or fibroscan, echography, electrocardiogram.
Study assessments at each study visit (1, 2, 4, 6, 8, 12 weeks) included: blood (HLG, ALT, AST, BT, BD, lipid profile, uric acid, electrolytes) and urine collection for testing, electrocardiogram (ECG) assessments, physical examinations and pregnancy test for females.
Results
We enrolled 24 patients (16 male and 8 female, aged between 32-64 years, median age 48 years), known to have chronic hepatitis C, out of which 6 patients null responder and 18 partial responder, with F3-F4 fibrosis by META-VIR score (Table 1) . The duration of the therapy association with DAA (Telaprevir 2250 mg/day, 750 mg at every 8 hours after eating) to the standard treatment was 3 months, with remarkable virulogical results meaning that after the utilization of the triple therapy a high rate of undetectable viremia was recorded at W12 in 83.3% of patients, while only two patients had detectable viremia at W12.
Tolerability was variable. Among the adverse reactions recorded, most frequent were: anemia 17 patients (70.8%), leucopenia, 10 patients (41.6%), thrombocitopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12,5%); hyperuricemia 8 patients (33,3%), hypocalcemia 4 patients (16.6%), loss of weight 4 patients (16,6%), anal pruritus (16,6%); only 2% of patients did not present any remarkable adverse reactions (Fig. 1, Table 2 ).
The laboratory results recorded in the study population are presented in table 3.
In cases with severe anemia the dose of ribavirin was reduced to 600 mg/day, without interruption of Telaprevir treatment. No serious adverse events requiring discontinuation of therapy were reported.
Discussion
The standard of care for treatment of HCV genotype 1 changed since the approval of two new DAA drugs (telaprevir and boceprevir) for use in pegylated interferonbased and ribavirin-based triple therapy in 2011 [5] . Until 2011, the standard therapy with pegylated interferon and ribavirin produced an SVR rate of approximately 40-50% for genotype 1 after 24-48 weeks of therapy [6] . Experience has shown improved response rates and treatment durations for many patients with genotype 1 HCV infection after DAA treatment, with SVR rates as high as 63-75% and reduction in duration of therapy by half for many patients. Telaprevir efficacy was initially proven in multiple large multicenter trials [7] [8] [9] [10] . As in our study, viral response after 12 weeks of triple therapy was 70-80% in prior null responders or partial responders.
In all clinical trials, the most common drug reactions to Telaprevir were rash, pruritus, anemia, nausea, hemorrhoids, diarrhea, anorectal discomforte, dysgeusia (alteration of taste), fatigue, vomiting and anal pruritus [7] [8] [9] [10] . Rash developed in 56% of study subjects and severe rash was reported in 4% of subjects who received Telaprevir combination therapy [7] [8] [9] [10] . In our study, no patient presented any form of rash.
Regarding anemia, clinical trials reported that 36% of patients had hemoglobin values less than or equal to 10 g/dL while hemoglobin values less than 8.5 g/dL were reported in 14% of them, similar to observations in our study.
Anorectal events were reported in 29% of subjects treated with Telaprevir combination treatment. The majority of these anorectal events included hemorrhoids, anorectal discomfort, anal pruritus and rectal burning which were mild to moderate in severity [7] [8] [9] [10] . In our study 4 patients (16,6%) had only anal pruritus which disappeared after the end of therapy.
Conclusions
Chronic HCV infection is a public health problem on both global and national level, predominantly affecting middle-age, socially and professionally active people. It requires involvement of specialists in the sense of a permanent optimization of therapy to maintain a well-balanced cost/efficiency. The triple therapy, with DAA added to the standard therapy, proves its utility despite the various adverse reactions recorded, the high rates of sustained viral reaction justifying its utilization.
Anemia is the most common adverse reaction and the patients in our study had the highest proportion of moderate form of anemia. Leucopenia was observed in the study in approximately 40% of patients, being predominantly mild and without notable implications on therapy.
Thrombocytopenia was present in 50% of patients, predominantly mild form which did not require any adjustment in the interferon dose.
